Previous 10 | Next 10 |
2023-03-23 12:47:58 ET Gainers: DiamondHead Holdings ( DHHCU ) +111% . DiamondHead Holdings ( DHHC ) +91% . Boxed BOXD +88% . ZyVersa Therapeutics ZVSA +33% . Amprius Technologies ( AMPX ) +30% . Kineta ( KA ) +29% . ...
2023-03-23 09:00:16 ET Advent Technologies Holdings ( ADN ) +34% enter into joint development pact. ZyVersa Therapeutics ( ZVSA ) +26% . BioSig Technologies ( BSGM ) +17% . Aziyo Biologics ( AZYO ) +14% Q4 Earnings call release Generatio...
2023-03-22 16:33:56 ET 89bio ( ETNB ) said Wednesday it commenced an underwritten public offering of $200 million of shares of its common stock, and pre-funded warrants to purchase its common stock. 89bio is expected to grant the underwriters of the offering an option for a period...
SAN FRANCISCO, March 22, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that ...
2023-03-22 13:29:15 ET Gainers: GameStop ( GME ) +41% . Telesis Bio ( TBIO ) +31% . EZGO Technologies ( EZGO ) +33% . CorEnergy Infrastructure ( CORR ) +28% . 89bio ( ETNB ) +25% . JanOne ( JAN ) +27% . InMed Phar...
2023-03-22 10:02:09 ET Gainers: 89bio ( ETNB ) +38% . SCYNEXIS ( SCYX ) +21% . Athersys ( ATHX ) +20% . Sol-Gel Technologies ( SLGL ) +19% . LifeMD ( LFMD ) +11% . Losers: NuCana ( NCNA ) -10% . Nutex Hea...
2023-03-22 08:21:40 ET 89bio ( ETNB ) +50% on topline data for NASH candidate. GameStop ( GME ) +48% on Q4 earnings. Telesis Bio ( TBIO ) +17% on Q4 earnings. Pyxis Oncology ( PYXS ) +11% on Q4 earnings. Ollie's Bargain O...
2023-03-22 07:44:35 ET Liver disease drug developer 89bio ( NASDAQ: ETNB ) added ~47% on Wednesday after announcing topline data from its Phase 2b ENLIVEN trial for pegozafermin in patients with nonalcoholic steatohepatitis (NASH). The trial involved 219 patients who wer...
- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage f...
2023-03-17 18:18:37 ET Summary As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer an intriguing solution for NASH. Early pegozafermin data showed extremely strong liver fat reduction as well as improvement in NASH. The upcomin...
News, Short Squeeze, Breakout and More Instantly...
2024-06-21 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week exten...
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)— —Regression of fibrosis by histology at month 24 will serve as the basis for potential accelerated approval...